CRISPR Therapeutics and Bayer announced the launch of their joint venture Casebia Therapeutics at the end of 2015. BioPharmaDIVE has now awarded the company a 2016 Dive Award in the category “Most Valuable Pharma Deal of the Year”, announced a statement.
Casebia Therapeutics develops drugs for blood disorders, blindness and congenital heart disease using the CRISPR/Cas-9 technology, which changes DNA. The method was developed by the French geneticist Emmanuelle Charpentier, who was also involved in the foundation of CRISPR Therapeutics. Last year, her technology was named ‘Breakthrough of the Year’ by the trade journal “Science”.
While other pharma mergers and acquisitions may have been more remarkable in economic terms, the joint venture’s focus on technological innovation made it a standout for the BioPharmaDIVE award, added the statement.
"We appreciate the industry recognition for the value of this really innovative partnership between CRISPR Therapeutics and Bayer," commented Rodger Novak, chief executive officer of CRISPR Therapeutics.
BioPharmaDIVE publishes news and analyses from the biopharma sector. Its readers make suggestions for the allocation of the annual awards, before industry experts and the BioPharmaDIVE editorial team crown the winners.
The significant role that Basel plays in the global pharma sector was highlighted by the selection of Joe Jimenez, Novartis CEO, as “Executive of the Year”.